Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Data Quality Monitoring in Clinical Trials: Has It Been Worth It? An Evaluation and Prediction of the Future by All Stakeholders.

by the CNS SUMMIT DATA QUALITY MONITORING WORKGROUP CORE MEMBERS., Daniel D, Kalali A, West M, Walling D, Hilt D, Engelhardt N, Alphs L, Loebel A, Vanover K, Atkinson S, Opler M, Sachs G, Nations K, Brady C.

Innov Clin Neurosci. 2016 Feb 1;13(1-2):27-33.

2.

Preclinical profile of ITI-214, an inhibitor of phosphodiesterase 1, for enhancement of memory performance in rats.

Snyder GL, Prickaerts J, Wadenberg ML, Zhang L, Zheng H, Yao W, Akkerman S, Zhu H, Hendrick JP, Vanover KE, Davis R, Li P, Mates S, Wennogle LP.

Psychopharmacology (Berl). 2016 Sep;233(17):3113-24. doi: 10.1007/s00213-016-4346-2.

3.

Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future.

Li P, Snyder GL, Vanover KE.

Curr Top Med Chem. 2016;16(29):3385-3403. Review.

4.

Phosphodiesterase Inhibition and Regulation of Dopaminergic Frontal and Striatal Functioning: Clinical Implications.

Heckman PR, van Duinen MA, Bollen EP, Nishi A, Wennogle LP, Blokland A, Prickaerts J.

Int J Neuropsychopharmacol. 2016 Apr 30. pii: pyw030. doi: 10.1093/ijnp/pyw030. [Epub ahead of print] Review.

5.

An Adenosine-Mediated Glial-Neuronal Circuit for Homeostatic Sleep.

Bjorness TE, Dale N, Mettlach G, Sonneborn A, Sahin B, Fienberg AA, Yanagisawa M, Bibb JA, Greene RW.

J Neurosci. 2016 Mar 30;36(13):3709-21. doi: 10.1523/JNEUROSCI.3906-15.2016.

6.

New approaches to treating Alzheimer's disease.

Zheng H, Fridkin M, Youdim M.

Perspect Medicin Chem. 2015 Feb 9;7:1-8. doi: 10.4137/PMC.S13210.

7.

Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission.

Snyder GL, Vanover KE, Zhu H, Miller DB, O'Callaghan JP, Tomesch J, Li P, Zhang Q, Krishnan V, Hendrick JP, Nestler EJ, Davis RE, Wennogle LP, Mates S.

Psychopharmacology (Berl). 2015 Feb;232(3):605-21. doi: 10.1007/s00213-014-3704-1.

8.

From single target to multitarget/network therapeutics in Alzheimer's therapy.

Zheng H, Fridkin M, Youdim M.

Pharmaceuticals (Basel). 2014 Jan 23;7(2):113-35. doi: 10.3390/ph7020113.

9.

Discovery of novel alpha7 nicotinic receptor antagonists.

Peng Y, Zhang Q, Snyder GL, Zhu H, Yao W, Tomesch J, Papke RL, O'Callaghan JP, Welsh WJ, Wennogle LP.

Bioorg Med Chem Lett. 2010 Aug 15;20(16):4825-30. doi: 10.1016/j.bmcl.2010.06.103.

10.

Nerve agent exposure elicits site-specific changes in protein phosphorylation in mouse brain.

Zhu H, O'Brien JJ, O'Callaghan JP, Miller DB, Zhang Q, Rana M, Tsui T, Peng Y, Tomesch J, Hendrick JP, Wennogle LP, Snyder GL.

Brain Res. 2010 Jun 25;1342:11-23. doi: 10.1016/j.brainres.2010.04.034.

11.

Role of 5-HT2A receptor antagonists in the treatment of insomnia.

Vanover KE, Davis RE.

Nat Sci Sleep. 2010 Jul 28;2:139-50.

Supplemental Content

Loading ...
Support Center